跳至主要内容
临床试验/EUCTR2012-005447-25-NL
EUCTR2012-005447-25-NL进行中(未招募)不适用

The use of Rienso, an ultrasmall superparamagnetic particle of iron-oxide, as a MRI contrast agent to image inflammation in the atherosclerotic plaque - INTIMA

Academic Medical Center Amsterdam, department of Internal Medicine0 个研究点开始时间: 2013年2月22日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients with established cardiovascular disease (one or more of the following)
  • - Coronary artery disease (e.g. myocardial infarction, angina pectoris, ischemic heart disease)
  • - Carotid artery disease, previous stroke or transient ischemic attack
  • - Aortic aneurysmatic disease
  • - Peripheral artery disease
  • Patients with an elevated cardiovascular risk (one or more of the following)
  • - BMI > 27
  • - Metabolic syndrome
  • - Diabetes mellitus type II
  • - Hypertension (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg)
  • - Reduced high-density lipoprotein
  • - Elevated low-density lipoprotein
  • Healthy volunteers
  • - Aged 40-80 years
  • - Not known with cardiovascular risk factors.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 30
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 30

排除标准

  • Active inflammatory diseases
  • History of anaphylaxis or other hypersensitivity reactions
  • History of iron overload
  • History of renal failure
  • History of abnormal liver function, or elevated liver enzymes.
  • Claustrophobia
  • Metal-containing material in the body or attached to the body

研究者

发起方
Academic Medical Center Amsterdam, department of Internal Medicine

相似试验